EFFECT OF EXOGENOUS TESTOSTERONE REPLACEMENT ON PROSTATE-SPECIFIC ANTIGEN AND PROSTATE-SPECIFIC MEMBRANE ANTIGEN LEVELS IN HYPOGONADAL MEN

被引:27
作者
DOUGLAS, TH
CONNELLY, RR
MCLEOD, DG
ERICKSON, SJ
BARREN, R
MURPHY, GP
机构
[1] WALTER REED ARMY MED CTR,DEPT SURG,UROL SERV,WASHINGTON,DC 20307
[2] WALTER REED ARMY MED CTR,DEPT CLIN INVEST,WASHINGTON,DC 20307
[3] UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,CTR PROSTATE DIS RES,BETHESDA,MD 20814
[4] PACIFIC NW CANC FDN,DIV CANC RES,SEATTLE,WA
关键词
ANDROGENS; TUMOR MARKERS; HYPOGONADISM; PROSTATE CANCER;
D O I
10.1002/jso.2930590410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have suggested that serum prostate-specific antigen (PSA) levels are under androgenic influence, especially in patients with adenocarcinoma of the prostate. PSMA (prostate-specific membrane antigen) is thought to reflect hormonal or clonal resistance or an independence with respect to testosterone regulation. The influence of testosterone on serum PSA expression in normal men is not clear. We studied the effect of exogenous testosterone administration on the serum levels of PSA and PSMA in hypogonadal men. Serial serum PSA, serum PSMA by Western blot, and serum total testosterone levels were obtained at intervals of every 2-4 weeks in 10 hypogonadal men undergoing treatment with exogenous testosterone, delivered as testosterone enanthate injection or by testosterone patch. Linear and quadratic orthogonal polynomial scores were calculated for PSMA, PSA, and testosterone. A 2-tailed, paired t-test failed to demonstrate a significant correlation between serum PSA (linear P = 0.432, quadratic P = 0.290) or PSMA (linear P = 0.162, quadratic P = 0.973) and serum testosterone levels. This study suggests that in hypogonadal men, neither PSMA nor PSA expression is testosterone-dependent, (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:246 / 250
页数:5
相关论文
共 16 条
[1]  
ANDREWS PE, 1992, CANCER RES, V52, P1525
[2]   INFLUENCE OF BENIGN PROSTATIC HYPERPLASIA, TESTOSTERONE AND AGE ON SERUM LEVELS OF PROSTATE-SPECIFIC ANTIGEN [J].
AUS, G ;
BERGDAHL, S ;
HUGOSSON, J ;
LODDING, P ;
NORLEN, L .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1994, 28 (04) :379-384
[3]  
BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
[4]   USING ORTHOGONAL POLYNOMIAL SCORES IN SUMMARIZING AND EVALUATING LONGITUDINAL DATA COLLECTED IN PHASE-I AND PHASE-II CLINICAL-PHARMACOLOGY STUDIES [J].
BRADSTREET, TE .
STATISTICS IN MEDICINE, 1993, 12 (07) :633-643
[5]   THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA [J].
GORMLEY, GJ ;
STONER, E ;
BRUSKEWITZ, RC ;
IMPERATOMCGINLEY, J ;
WALSH, PC ;
MCCONNELL, JD ;
ANDRIOLE, GL ;
GELLER, J ;
BRACKEN, BR ;
TENOVER, JS ;
VAUGHAN, ED ;
PAPPAS, F ;
TAYLOR, A ;
BINKOWITZ, B ;
NG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1185-1191
[6]   ANDROGENS UP-REGULATE THE HUMAN PROSTATE-SPECIFIC ANTIGEN MESSENGER-RIBONUCLEIC-ACID (MESSENGER-RNA), BUT DOWN-REGULATE THE PROSTATIC ACID-PHOSPHATASE MESSENGER-RNA IN THE LNCAP CELL-LINE [J].
HENTTU, P ;
LIAO, SS ;
VIHKO, P .
ENDOCRINOLOGY, 1992, 130 (02) :766-772
[7]  
ISRAELI RS, 1994, CANCER RES, V54, P1807
[8]   REGULATION OF PROLIFERATION AND PRODUCTION OF PROSTATE-SPECIFIC ANTIGEN IN ANDROGEN-SENSITIVE PROSTATIC-CANCER CELLS, LNCAP, BY DIHYDROTESTOSTERONE [J].
LEE, C ;
SUTKOWSKI, DM ;
SENSIBAR, JA ;
ZELNER, D ;
KIM, I ;
AMSEL, I ;
SHAW, N ;
PRINS, GS ;
KOZLOWSKI, JM .
ENDOCRINOLOGY, 1995, 136 (02) :796-803
[9]  
Macindoe John H., 1995, Journal of Urology, V153, p397A
[10]   HORMONAL-THERAPY OF MALE HYPOGONADISM [J].
MATSUMOTO, AM .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1994, 23 (04) :857-875